Current understandings in treating children with steroid-resistant nephrotic syndrome

37Citations
Citations of this article
128Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Steroid-resistant nephrotic syndrome (SRNS) remains a challenge for paediatric nephrologists. SRNS is viewed as a heterogeneous disease entity including immune-based and monogenic aetiologies. Because SRNS is rare, treatment strategies are individualized and vary among centres of expertise. Calcineurin inhibitors (CNI) have been effectively used to induce remission in patients with immune-based SRNS; however, there is still no consensus on treating children who become either CNI-dependent or CNI-resistant. Rituximab is a steroid-sparing agent for patients with steroid-sensitive nephrotic syndrome, but its efficacy in SRNS is controversial. Recently, several novel monoclonal antibodies are emerging as treatment option, but their efficacy remains to be seen. Non-immune therapies, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have been proven efficacious in children with SRNS and are recommended as adjuvant agents. This review summarizes and discusses our current understandings in treating children with idiopathic SRNS.

Cite

CITATION STYLE

APA

Lee, J. M., Kronbichler, A., Shin, J. I., & Oh, J. (2021, April 1). Current understandings in treating children with steroid-resistant nephrotic syndrome. Pediatric Nephrology. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00467-020-04476-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free